Pilon-Thomas S - Search Results

1

Neoantigen-specific CD4⁺ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.

Hall MS, Teer JK, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, Nagle L, Scott E, Schachner B, Innamarato P, Hall AM, Blauvelt J, Rich CJ, Richards AD, Ceccarelli J, Langer TJ, Yoder SJ, Beatty MS, Cox CA, Messina JL, Abate-Daga D, Mule JJ, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Hall MS, et al. Among authors: pilon thomas s. J Immunother Cancer. 2023 Oct;11(10):e007288. doi: 10.1136/jitc-2023-007288. J Immunother Cancer. 2023. PMID: 37802604 Free PMC article.

2

SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021.

Giuliano AR, Pilon-Thomas S, Schell MJ, Abrahamsen M, Islam JY, Isaacs-Soriano K, Kennedy K, Dukes CW, Whiting J, Rathwell J, Hensel JA, Mangual LN, Schonbrunn E, Bikowitz M, Grassie D, Yang Y. Giuliano AR, et al. Emerg Infect Dis. 2022 Mar;28(3):556-563. doi: 10.3201/eid2803.211495. Epub 2022 Jan 26. Emerg Infect Dis. 2022. PMID: 35081021 Free PMC article.

3

Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.

Asavaroengchai W, Kotera Y, Koike N, Pilon-Thomas S, Mulé JJ. Asavaroengchai W, et al. Biol Blood Marrow Transplant. 2004 Aug;10(8):524-33. doi: 10.1016/j.bbmt.2004.04.003. Biol Blood Marrow Transplant. 2004. PMID: 15282530 Free article.

4

Dendritic cell-based therapeutics for breast cancer.

Pilon-Thomas SA, Verhaegen ME, Mulé JJ. Pilon-Thomas SA, et al. Breast Dis. 2004;20:65-71. doi: 10.3233/bd-2004-20108. Breast Dis. 2004. PMID: 15687708 Review.

5

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.

Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, Jove R, Pardoll D, Yu H. Kortylewski M, et al. Nat Med. 2005 Dec;11(12):1314-21. doi: 10.1038/nm1325. Epub 2005 Nov 20. Nat Med. 2005. PMID: 16288283

6

Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.

Pilon-Thomas S, Verhaegen M, Kuhn L, Riker A, Mulé JJ. Pilon-Thomas S, et al. Cancer Immunol Immunother. 2006 Oct;55(10):1238-46. doi: 10.1007/s00262-005-0104-8. Epub 2005 Nov 29. Cancer Immunol Immunother. 2006. PMID: 16315029 Free PMC article.

7

Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.

Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mulé JJ, Riker AI. Pilon-Thomas S, et al. J Immunother. 2006 Jul-Aug;29(4):381-7. doi: 10.1097/01.cji.0000199199.20717.67. J Immunother. 2006. PMID: 16799333

8

Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.

Koike N, Pilon-Thomas S, Mulé JJ. Koike N, et al. J Immunother. 2008 May;31(4):402-12. doi: 10.1097/CJI.0b013e31816cabbb. J Immunother. 2008. PMID: 18391755

9

TNF-alpha-treated DC exacerbates disease in a murine tumor metastasis model.

Vohra N, Verhaegen M, Martin L, Mackay A, Pilon-Thomas S. Vohra N, et al. Cancer Immunol Immunother. 2010 May;59(5):729-36. doi: 10.1007/s00262-009-0793-5. Cancer Immunol Immunother. 2010. PMID: 19921187 Free PMC article.

10

Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.

Matsushita N, Komine H, Grolleau-Julius A, Pilon-Thomas S, Mulé JJ. Matsushita N, et al. Cancer Immunol Immunother. 2010 Jun;59(6):875-84. doi: 10.1007/s00262-009-0813-5. Epub 2010 Jan 8. Cancer Immunol Immunother. 2010. PMID: 20054688 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page